Hair loss and restoration
For arthritis patients, document grip strength or time to complete daily tasks
In addition to supporting weight loss, GLP-1, GIP, and combination therapies have also been shown to improve key health markers associated with obesity
Moreover, efpeglenatide therapy reduced the risk of CV disease by about 27% compared to the placebo in the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) study [51]
Medication Options During Maintenance Continuing Semaglutide or Tirzepatide For some adults, continued GLP-1 therapy may be medically appropriate because obesity is a chronic condition
Forsberg JT, Martinussen M, Flaten MA